Mankind Pharma
| Company type | Public |
|---|---|
| ISIN | INE634S01028 |
| Industry | Pharmaceutical |
| Founded | 1991 |
| Founders |
|
| Headquarters | , |
Area served | Worldwide |
Key people | |
| Products | |
| Revenue | ₹12,207 crore (US$1.4 billion) (2025) |
| ₹3,030 crore (US$360 million) (2025) | |
| ₹2,007 crore (US$240 million) (2025) | |
| Total assets | ₹27,759 crore (US$3.3 billion) (2025) |
| Total equity | ₹14,568 crore (US$1.7 billion) (2025) |
Number of employees | 22,000+ (2023) |
| Website | www |
| Footnotes / references Financials as of 31 March 2025. | |
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.
As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception.